223 related articles for article (PubMed ID: 31597135)
1. Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications.
Lin S; Zhang A; Zhang X; Wu ZB
Neuroendocrinology; 2020; 110(6):477-488. PubMed ID: 31597135
[TBL] [Abstract][Full Text] [Related]
2. The Role of Dopamine Agonists in Pituitary Adenomas.
Giraldi EA; Ioachimescu AG
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
[TBL] [Abstract][Full Text] [Related]
3. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
4. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
6. Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
Portari LHC; Correa-Silva SR; Abucham J
Neuroendocrinology; 2022; 112(1):68-73. PubMed ID: 33477154
[TBL] [Abstract][Full Text] [Related]
7. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
8. Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy.
Brichta CM; Wurm M; Krebs A; Schwab KO; van der Werf-Grohmann N
J Pediatr Endocrinol Metab; 2019 Sep; 32(9):969-977. PubMed ID: 31323004
[TBL] [Abstract][Full Text] [Related]
9. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
10. The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma.
Gürbüz F; Yağcı-Küpeli B; Kör Y; Yüksel B; Zorludemir S; Gürbüz BB; Küpeli S
J Pediatr Endocrinol Metab; 2014 Jan; 27(1-2):159-63. PubMed ID: 23945126
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
12. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
13. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
Delgrange E; Donckier J
J Clin Endocrinol Metab; 1997 Aug; 82(8):2755-6. PubMed ID: 9253367
[No Abstract] [Full Text] [Related]
14. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
[TBL] [Abstract][Full Text] [Related]
15. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.
Behan LA; Draman MS; Moran C; King T; Crowley RK; O'Sullivan EP; Smith D; Thompson CJ; Agha A
Pituitary; 2011 Dec; 14(4):362-6. PubMed ID: 19191028
[TBL] [Abstract][Full Text] [Related]
16. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
17. A Case Report of Delusions in a Patient Receiving Cabergoline Therapy for Prolactinoma: Pathophysiology and Proposed Treatment With Aripiprazole.
Springer C; Rodgers R; Vivino G; Attanagoda S; Miks CD
Clin Neuropharmacol; 2023 May-Jun 01; 46(3):126-127. PubMed ID: 37191567
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma.
Fusco A; Lugli F; Sacco E; Tilaro L; Bianchi A; Angelini F; Tofani A; Barini A; Lauriola L; Maira G; Pontecorvi A; de Marinis L
Pituitary; 2011 Dec; 14(4):351-7. PubMed ID: 19152032
[TBL] [Abstract][Full Text] [Related]
19. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
[TBL] [Abstract][Full Text] [Related]
20. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
